Pacla Medical Limited
Pacla Medical Ltd is a health care device company developing a new generation robotic physiotherapy device (‘Robo-Physio’) to improve the symptoms of Multiple Sclerosis (MS), chronic back pain and other conditions. Current interventions for MS and back pain offer limited clinical benefits, with many patients dependent on drugs or mobility aids.
Pacla Medical ’s prototype device, Robo-Physio, has 36 robotic ‘fingers’ designed to gently move towards/away from the spine. The ‘fingers’ are adjustable to accommodate different back curvatures in depth, side-to-side, and length, and can provide a consistent therapy at a time and place of the patient’s choosing without the need for a trained therapist to be present.
The Company’s accompanying SPINE MAP software installed within the device monitors the individual finger’s pressure variations representing tissue tension at each vertebra.
Personalised for each individual, the device allows treatment in the home to support self-management for patients without a professional practitioner being present. The Company will initially target MS and chronic back pain sufferers, a high profile market segment, and the device also has the potential to benefit patients with other conditions such as Parkinson’s Disease.
In the UK, 2 million people have recurring back pain which results in a total cost of £12.3 billion (22% of UK healthcare expenditure). Management of chronic pain patients in primary care in the UK accounts for 4.6 million appointments per year, equivalent to 793 whole time GPs, at a total cost of around £69 million. Please see Item 4. In the UK, an estimated 10 million working days were lost due to back pain in 2015, equivalent to £1 billion in lost earnings .
The prevalence of chronic back pain is forecast to rise due to a number of factors, including an ageing population as well as an increasing incidence of obesity.
Currently, the global physiotherapy equipment market is steadily growing and is forecast to reach a value of around US$24.7bn by 2022, up from the value recorded in 2015 of US$15bn . Pacla Medical states that the market is anticipated to expand at a compounded annual growth rate of 6.8% during the forecast period of 2015-2022.